The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


TREVICTA



Janssen-Cilag International NVEU/1/14/971/010

Main Information

Trade NameTREVICTA
Active SubstancesPaliperidone palmitate (r092670)
Dosage FormProlonged-release suspension for injection
Licence HolderJanssen-Cilag International NV
Licence NumberEU/1/14/971/010

Group Information

ATC CodeN05AX Other antipsychotics
N05AX13 paliperidone

Status

License statusAuthorised
Licence Issued26/05/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back